118 results
10-K
2016 FY
EX-10.12
SYRS
Syros Pharmaceuticals Inc.
20 Mar 17
Annual report
12:00am
the “at-will” nature of your employment, in the event your employment is terminated by the Company without Cause or by you for Good Reason (each … agreement to sign and adhere to the provisions of this Agreement. The Employee further acknowledges that the nature of the Company's business
8-K
EX-10.1
SYRS
Syros Pharmaceuticals Inc.
13 Oct 21
Departure of Directors or Certain Officers
4:01pm
in such benefit plans, may be changed by the Company at any time without advance notice.
4. Without otherwise limiting the “at-will” nature of your … of this Agreement. You further acknowledge that the nature of Syros’ business is such that protection of its proprietary and confidential information
8-K
EX-99.1
qggyvu
26 May 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
y2i2x0i fw0m9l0x6ly
2 Dec 19
Regulation FD Disclosure
7:03am
8-K
EX-99.1
yarq8ha6y2l0je 0jk
13 Jan 20
Regulation FD Disclosure
6:11am
8-K
EX-99.1
1mrwq7wxi9ci 57tnh
25 Feb 21
Regulation FD Disclosure
7:01am
8-K
EX-99.1
7rp il30v7nf
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.1
byt8bjl
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
EX-2.1
iu1aupnff 5z8276b
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.2
rvuerhxj2ge ywbz83
6 Jul 22
Other Events
4:27pm
8-K
mrpvracr4 v2
21 Jul 23
Termination of a Material Definitive Agreement
4:36pm
8-K
EX-10.1
iz7ops
11 Jan 19
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-2.1
m4eo50wr
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
D
au2g9vdspy9so
22 Aug 12
$1.25M in equity, sold $1.25M, 4 investors
12:00am